Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
MUC5B-promotervariant rs35705950 risicofactor voor RA-geassocieerde ILD
feb 2019 | ILD, Pneumonie, RA